Version May 2024
Given the potency of contemporary antiviral regimens, patients who miss a few doses intermittently do not jeopardize their likelihood of treatment success, and we counsel them to restart and continue the regimen for the originally planned duration (making up for the missed doses).
Our approach in this algorithm is consistent with AASLD/IDSA recommendations for managing multiple missed consecutive doses during initial therapy of chronic HCV infection with sofosbuvir-velpatasvir or glecaprevir-pibrentasvir in patients without decompensated cirrhosis. This approach does not apply to patients treated with other regimens or to those with decompensated cirrhosis.AASLD: American Association for the Study of Liver Diseases; DAA: direct-acting antiviral; HCV: hepatitis C virus; IDSA: Infectious Diseases Society of America; RNA: ribonucleic acid; SVR: sustained virologic response.
* The total duration should make up for the antiviral doses that the patient missed.
¶ The HCV RNA should be checked as soon as possible, ideally on the same day as restarting the regimen; however, patients should not delay restarting the regimen in order to have the HCV RNA checked.
Δ Although the recommendation to extend the duration in these circumstances is consistent with the AASLD/IDSA guidelines, it may not be feasible if payers do not provide coverage for the extension.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
